Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic stem cell transplantation for children and Adolescents with CML: Conditioning regimen, donor selection, supportive care and diagnostic procedures

Next Previous
Trial Profile

Allogeneic stem cell transplantation for children and Adolescents with CML: Conditioning regimen, donor selection, supportive care and diagnostic procedures

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Melphalan (Primary) ; Thiotepa (Primary) ; Antithymocyte globulin; Ciclosporin; Ciclosporin; Mycophenolate mofetil
  • Indications Chronic myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms CML-SCT-IBFM

Most Recent Events

  • 01 Jul 2024 Results assessing safety and the efficacy of a thiotepa/melphalan-based reduced intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) in children and adolescents with chronic myeloid leukaemia (CML) in chronic phase , published in the British Journal of Haematology.
  • 14 Apr 2021 Status changed from active, no longer recruiting to completed.
  • 05 Feb 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (Global end date:2020-12-01)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top